Intravenous Methadone for Severe Cancer Pain: A Presentation of 10 Cases

Table 2

Intravenous methadone.

Patients	VAS T0*(/10)	Starting dose; (mg/day)	Ketamine; (mg/day)	VAS T24* (/10)	Final dose; (mg/day)	Ketamine; (mg/day)	VAS (end of treatment* (/10)	Duration; (days)
1	8	400	150	4	700	500	0-1	59
2	8	80	/	0	80	/	0–3	2
3	9	200	200	5	400	960	0	24
4	8	100	200	0	100	200	<3	9
5	8	100	/	4	120	/	0	7
6	7	80	/	4	200	/	2	11
7	9	30	/	0	30	/	0	7
8	8	20	50	4	25	50	0	14
9	8	30	/	3	30	/	0–2	10
10	9	100	100	4	90	80	<3	25

∗On average.